Allogene Therapeutics Inc (ALLO) Stock Price, Quote & News

Company Profile

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineer...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 457 2700

Website: allogene.com

Address:

210 East Grand Avenue, South San Francisco, United States

Mr_JokeR Jul. 11 at 4:35 PM

$INKT one day $ALLO ... one day...

0 · Reply

tradersunion353 Jul. 11 at 3:56 PM

$ALLO Huge insider selling at 1.16 range Dont fall for pumpers Folks here are not smarter than those insiders selling shares at these levels

0 · Reply

tradersunion353 Jul. 11 at 3:55 PM

$ALLO Huge insider selling going on . Reverse split coming soon after this drops to 50 cents

0 · Reply

Malandrosky Jul. 11 at 2:47 PM

$NKTX $ALLO how do $INKT results affect us? I think it’s bullish no?

1 · Reply

lucabrix Jul. 11 at 8:54 AM

$ALLO a spike could be on the way!!!!

0 · Reply

lucabrix Jul. 10 at 7:24 PM

$ALLO volume is ripping with price, hold tight!!

0 · Reply

Lisan_AlGaib Jul. 10 at 4:45 PM

$ALLO can someone do a welfare check on this poster? i am concern.

1 · Reply

elvisvandelay Jul. 10 at 4:42 PM

$ALLO something happened here not sure what and why...

1 · Reply

LIVE_Trading Jul. 10 at 4:41 PM

$ALLO Almost ready to go after popping $SPY $QQQ $NVDA $TSLA

0 · Reply

tradersunion353 Jul. 10 at 1:44 PM

$ALLO Dead company Heavy insider selling Dropped from $48 to $1 Too many paid pumpers All signs indicate this stock is heading no where

0 · Reply

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

May 29, 2025, 3:37 PM EDT - 6 weeks ago

Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment

May 28, 2025, 9:43 AM EDT - 6 weeks ago

Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade)

May 23, 2025, 8:30 AM EDT - 7 weeks ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

May 22, 2025, 5:17 PM EDT - 7 weeks ago

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

May 13, 2025, 10:47 PM EDT - 2 months ago

Allogene Therapeutics, Inc. (ALLO) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:05 PM EDT - 2 months ago

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

May 6, 2025, 8:30 AM EDT - 2 months ago

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

Apr 23, 2025, 10:12 AM EDT - 2 months ago

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 7, 2025, 8:30 AM EDT - 3 months ago

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Mar 13, 2025, 11:56 PM EDT - 4 months ago

Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 4:02 PM EDT - 4 months ago

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Mar 3, 2025, 8:30 AM EST - 4 months ago

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Feb 26, 2025, 10:52 AM EST - 4 months ago

Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities

Feb 26, 2025, 8:30 AM EST - 4 months ago

Allogene Therapeutics Announces Participation in March Investor Conference

Feb 25, 2025, 4:10 PM EST - 4 months ago

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

Feb 24, 2025, 10:53 PM EST - 4 months ago

Allogene Therapeutics: Disrupting CAR-T With A Scalable Model

$Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology$

Feb 13, 2025, 4:30 PM EST - 5 months ago

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

Jan 28, 2025, 8:30 AM EST - 5 months ago

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

Dec 16, 2024, 8:30 AM EST - 7 months ago

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 12, 2024, 8:30 AM EST - 7 months ago

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

Nov 19, 2024, 8:30 AM EST - 8 months ago

Allogene Therapeutics Announces Participation in December Investor Conferences

Nov 18, 2024, 8:30 AM EST - 8 months ago

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Nov 7, 2024, 8:59 PM EST - 8 months ago

Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:02 PM EST - 8 months ago

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

Nov 7, 2024, 10:00 AM EST - 8 months ago

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

Nov 5, 2024, 9:10 AM EST - 8 months ago

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 30, 2024, 8:30 AM EDT - 9 months ago

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

Oct 2, 2024, 4:11 PM EDT - 10 months ago

Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity

Sep 30, 2024, 8:30 AM EDT - 10 months ago

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

Aug 26, 2024, 11:39 PM EDT - 11 months ago

Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies

Aug 10, 2024, 12:34 AM EDT - 1 year ago

Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:02 PM EDT - 1 year ago

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

Jul 31, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

Jul 1, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

Jun 20, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

Jun 12, 2024, 1:09 PM EDT - 1 year ago

Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products

May 23, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

May 13, 2024, 7:31 PM EDT - 1 year ago

Allogene Therapeutics, Inc. (ALLO) Q1 2024 Earnings Call Transcript

May 13, 2024, 4:47 PM EDT - 1 year ago

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

May 13, 2024, 4:01 PM EDT - 1 year ago

Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

May 6, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

Apr 26, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

Apr 9, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Announces Q2 Investor Conference Participation

Apr 4, 2024, 11:30 AM EDT - 1 year ago

Showcasing Seeking Alpha's March 2024 New Analysts

APD AXP CPS CPT DG DK EPR

Mar 14, 2024, 8:49 PM EDT - 1 year ago

Allogene Therapeutics, Inc. (ALLO) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 4:05 PM EDT - 1 year ago

Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

Mar 12, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease

Mar 5, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

Feb 28, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference

Mr_JokeR Jul. 11 at 4:35 PM

$INKT one day $ALLO ... one day...

0 · Reply

tradersunion353 Jul. 11 at 3:56 PM

$ALLO Huge insider selling at 1.16 range Dont fall for pumpers Folks here are not smarter than those insiders selling shares at these levels

0 · Reply

tradersunion353 Jul. 11 at 3:55 PM

$ALLO Huge insider selling going on . Reverse split coming soon after this drops to 50 cents

0 · Reply

Malandrosky Jul. 11 at 2:47 PM

$NKTX $ALLO how do $INKT results affect us? I think it’s bullish no?

1 · Reply

lucabrix Jul. 11 at 8:54 AM

$ALLO a spike could be on the way!!!!

0 · Reply

lucabrix Jul. 10 at 7:24 PM

$ALLO volume is ripping with price, hold tight!!

0 · Reply

Lisan_AlGaib Jul. 10 at 4:45 PM

$ALLO can someone do a welfare check on this poster? i am concern.

1 · Reply

elvisvandelay Jul. 10 at 4:42 PM

$ALLO something happened here not sure what and why...

1 · Reply

LIVE_Trading Jul. 10 at 4:41 PM

$ALLO Almost ready to go after popping $SPY $QQQ $NVDA $TSLA

0 · Reply

tradersunion353 Jul. 10 at 1:44 PM

$ALLO Dead company Heavy insider selling Dropped from $48 to $1 Too many paid pumpers All signs indicate this stock is heading no where

0 · Reply

JoshThe3rd Jul. 10 at 4:09 AM

$ALLO Darwin Global has a position now. Darwin specializes in finding biotechs that get bought out. While his small bets are hit or miss he is still very good at finding attractive M&A opportunities and I always pay attention.

3 · Reply

tradersunion353 Jul. 9 at 6:06 PM

$ALLO Reverse split will he announced as soon as it drops to 50 cents

1 · Reply

tradersunion353 Jul. 9 at 12:27 AM

$ALLO Once this drops to 50 cents . Lazy insiders may announce reverse split

1 · Reply

TonyCos Jul. 8 at 11:01 AM

$ALLO Here's a breakdown of the predictions and forecasts: Average Price Target: The average twelve-month price target for ALLO from 10 analysts is $8.44, with a high of $14.00 and a low of $4.00. Forecasted Upside: This average target represents a significant potential upside of 627.97% from the current price of $1.16 as of July 7, 2025. Analyst Ratings: MarketBeat (July 7, 2025): 9 analysts recommend "Buy" and 1 recommends "Hold". Stock Analysis (May 15, 2025): 9 analysts have a consensus rating of "Strong Buy".

1 · Reply

tradersunion353 Jul. 5 at 7:35 PM

$ALLO At this rate of stock falling under 1 dollar. Reverse split is very much possible

0 · Reply

tradersunion353 Jul. 5 at 7:34 PM

$ALLO Ceo sold his shares at 1 dollar range Paid pumpers here knows better than ceo who runs the company Huge insider selling going on . Dont fall for paid pumpers

0 · Reply

Highbred Jul. 3 at 3:07 PM

$ALLO potential is there.....standing by for fireworks..,

0 · Reply

tradersunion353 Jul. 3 at 3:04 PM

$ALLO Huge insider selling going on at these levels This is going to drop to 50 cents Expect a reverse split once it drops to 50 cents

1 · Reply

tradersunion353 Jul. 3 at 2:56 PM

$ALLO Reverse split coming soon

0 · Reply

lucabrix Jul. 2 at 7:26 PM

$ALLO Volume incresing, mind the 1.26 upper resistance

1 · Reply

Lisan_AlGaib Jul. 2 at 3:20 PM

$ALLO Ok. Thank you for your input.

0 · Reply

lucabrix Jul. 2 at 2:59 PM

$ALLO Ready to spike!

0 · Reply

Market Cap	279.98M
Revenue (ttm)	20,000.00
Net Income (ttm)	-257.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,287,950.01%
Debt to Equity Ratio	0.00

Volume	2,907,300
Avg Vol	3,528,744
Day's Range	N/A - N/A
Shares Out	218.73M
Stochastic %K	77%
Beta	0.31
Analysts	Strong Sell
Price Target	$8.05